


AMENDMENT OF THE CLAIMS:

1. (Currently amended) A compound of formula (I):



wherein A⁻ ~~represents~~is the benzenesulphonate (besylate) anion;

R ~~represents~~is H or C₁₋₆ alkyl; and

n is a number from 0.8 to 2.2.

2. (Currently amended) A compound of formula (I) according to claim 1

wherein R ~~represents~~is H.


3. (Currently amended) A compound of formula (I) according to claim 1 ~~or~~

~~claim 2~~ wherein n ~~represents~~is a number between 1.1 and 2.1.

4. (Currently amended) A compound of formula (I) according to claim 1 ~~any one~~
~~of claims 1 to 3~~ wherein n is about 2.

5. (Currently amended) A compound according to claim 1 ~~any one of claims 1 to~~
4 which is 4-({[({[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)carbonyl]amino} methyl)benzamide benzenesulfonate dihydrate.

6. (Original) A process for the preparation of a compound of formula (I) as defined
in claim 1, which process comprises the reaction of a compound of formula (IA);



with a source of the besylate anion and a suitable C₁₋₆alkanol and water.


7. (Currently amended) A compound of formula (I) as defined in claim 1 for use as a therapeutic agent, ~~particularly~~ in the treatment of patients with inflammatory conditions, ~~eg. asthma or rhinitis~~.

8. (Currently amended) A method of manufacture of a medicament comprising the step of incorporating ~~Use of a compound of formula (I) as defined in claim 1 for the manufacture of in a pharmaceutical composition. a medicament for the treatment of inflammatory conditions, eg. asthma or rhinitis.~~


9. (Currently amended) A method for the treatment of a human or animal subject suffering from or susceptible to an inflammatory condition ~~eg. asthma or rhinitis~~, which method comprises administering to said human or animal subject an effective amount of a compound of formula (I) as defined in claim 1.

10. (Original) A pharmaceutical composition, comprising a compound of formula (I) as defined in claim 1 optionally with one or more physiologically acceptable diluents or carriers.


11. (Currently amended) A compound of formula (IIA)



12. (Currently amended) A compound of formula (IIBR)



13. (Currently amended) A compound of formula (IIB)



14. (new) The method of treatment of claim 9, wherein the inflammatory condition is asthma.

15. (new) The method of treatment of claim 9, wherein the inflammatory condition is rhinitis.